Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Monatide (IMS 3015)

DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.

MPHOSPH1 and DEPDC1

Tomoaki Fujioka, M.D. & Ph.D.

The purpose of this study is to evaluate the safety and clinical efficacy of novel vaccination for advanced bladder cancer.

DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified using genome-wide expression profile analysis by the use of cDNA microarray in our previous studies. We have determined the HLA-A\*2402 restricted epitope peptides derived from DEPDC1, DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed strong IFN-g production when stimulated with the appropriate targets expressed the appropriate protein and HLA-A\*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined after the vaccination. Therefore we focused on the safety and efficacy of novel vaccination for the advanced bladder cancer patients who already showed resistance to standard chemotherapies or radiotherapy.

Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer

Human Genome Center, Institute of Medical Science, University of Tokyo

Iwate Medical University

Department of Urology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	NCT00635336	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer	NCT00635336	Bladder Cancer	MPHOSPH1 and DE...	20 Years - 80 Years	Iwate Medical University

Spots Global Cancer Trial Database for advanced bladder cancer which showed resistance for standard treatments